Skip to content

Treatment of Temporomandibular Dysfunction With Hypertonic Dextrose Injection

Treatment of Temporomandibular Dysfunction With Hypertonic Dextrose Injection: A Randomised Clinical Trial of Efficacy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01617356
Enrollment
30
Registered
2012-06-12
Start date
2012-06-30
Completion date
2017-05-31
Last updated
2018-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Temporomandibular Joint Disorders

Keywords

TMD, temporomandibular, dextrose, prolotherapy

Brief summary

Dysfunction of the jaw, associated with pain in the jaw or about the jaw in the face can be quite long lasting and debilitating. Dextrose injection with a small needle has be notably helpful in preliminary studies in reducing pain and improving jaw function. This randomized trial will compare dextrose injection with saline injection for temporomandibular(jaw) dysfunction, also known as TMD.

Detailed description

Longitudinal studies of subjects with temporomandibular dysfunction show a general pattern of symptom diminishment, especially in the elderly. However studies out to 2-8 years show residual symptoms in many and nearly 25% with unabated symptoms. Dextrose injection has been utilized empirically for many years and a marked reduction in pain and luxation after intraarticular and pericapsular dextrose injection has been reported in a recent RCT. However, small study size and lack of a non injection control have prevented any definitive conclusions as the additional efficacy of including dextrose in the injectate. The mechanism of action of dextrose injection was originally thought to be via a brief stimulation of the inflammatory cascade with resultant production of growth factors. However, non-inflammatory dextrose effects on growth factor production have been demonstrated, and, more recently, dextrose has been found to treat neurogenic inflammation (pain from upregulation of the TRPV1 receptor on peptidergic nerves). This has the theoretical benefit of reducing pain, regardless of the status and position of the intraarticular cartilage or degree of degenerative change of the TMD. The primary goal of this study is to evaluate the ability of dextrose injection versus saline injection to reduce pain and improve functional complaints referable to the temporomandibular joint.

Interventions

Injection at 0, 1, and 2 months of 1 ml of a solution consisting of 20% dextrose and 0.2% lidocaine.

OTHERInjection of 1 ml of 0.8 SW/0.2% lidocaine

Injection at 0, 1, and 2 months of 1 ml of a solution consisting of 0.8 sterile water and 0.2% lidocaine.

Sponsors

Zarate, Miguel, M.D.
CollaboratorINDIV
Frusso, Ricardo, M.D.
Lead SponsorINDIV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
19 Years to 90 Years
Healthy volunteers
Yes

Inclusion criteria

* Facial Pain NRS rating \> 5/10 * Jaw symptom rating \> 5/10 * Jaw function issues seen on examination

Exclusion criteria

* Any potential acute dental issue * Rheumatic inflammatory disease * Chronic intake of NSAIDs or corticosteroids. * Pain in other body location worse than jaw pain * Pain 10/10 in other body location.

Design outcomes

Primary

MeasureTime frameDescription
50% or more improvement in 0-10 Numerical Rating Scale (NRS) for for jaw dysfunction from baseline to 1 year1 yearAnchors include 0 = no pain and 10 = worst pain imaginable. A 50% reduction in the 0-10 NRS is a clinically important outcome.
50% or more improvement in 0-10 Numerical Rating Scale (NRS) for for jaw pain from baseline to 1 year1 yearAnchors include 0 = no pain and 10 = worst pain imaginable. A 50% reduction in the 0-10 NRS is a clinically important outcome.
Change from baseline to 1 year in a 0-10 Numerical Rating Scale (NRS) for Jaw Dysfunction1 yearAnchors include 0 = no pain and 10 = worst pain imaginable An improvement is a reduction in the NRS scale.
Change from baseline to 3 months in a 0-10 Numerical Rating Scale (NRS) for Jaw Pain3 monthsAnchors include 0 = no pain and 10 = worst pain imaginable An improvement is a reduction in the NRS scale.
50% or more improvement in 0-10 Numerical Rating Scale (NRS) for Jaw pain from baseline to 3 months3 monthsAnchors include 0 = no pain and 10 = worst pain imaginable. A 50% reduction in the 0-10 NRS is a clinically important outcome.
Change from baseline to 3 months in a 0-10 Numerical Rating Scale (NRS) for jaw dysfunction.3 monthsAnchors include 0 = no pain and 10 = worst pain imaginable An improvement is a reduction in the NRS scale.
50% or more improvement in 0-10 Numerical Rating Scale (NRS) for for jaw dysfunction to 3 months3 monthsAnchors include 0 = no pain and 10 = worst pain imaginable. A 50% reduction in the 0-10 NRS is a clinically important outcome.
Change from baseline to 1 year in a 0-10 Numerical Rating Scale (NRS) for jaw pain1 yearAnchors include 0 = no pain and 10 = worst pain imaginable An improvement is a reduction in the NRS scale.

Secondary

MeasureTime frameDescription
Satisfaction to 3 months as measured by a 0-10 Numerical Rating Scale (NRS)3 monthsAnchors include 0 = no satisfaction and 10 = complete satisfaction
Change in mouth opening in millimeters from baseline to 3 months as manually measured by a Therabite.3 monthsAn increase in mouth opening in millimeters is considered an improvement in this study.

Countries

Argentina

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 17, 2026